{"id":"fluvastatin-ezetimibe","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Elevated liver transaminases"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Gastrointestinal disturbance"}]},"_chembl":{"chemblId":"CHEMBL2220442","moleculeType":"Small molecule","molecularWeight":"411.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluvastatin is an HMG-CoA reductase inhibitor that blocks hepatic cholesterol synthesis, while ezetimibe inhibits Niemann-Pick C1-like 1 (NPC1L1) protein to reduce intestinal cholesterol absorption. Together, they provide complementary mechanisms to lower LDL cholesterol levels more effectively than either agent alone.","oneSentence":"This combination reduces LDL cholesterol through dual inhibition of cholesterol synthesis and intestinal absorption.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:07.804Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and mixed dyslipidemia"}]},"trialDetails":[{"nctId":"NCT06501443","phase":"PHASE4","title":"LATAM LOWERS LDL-C","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-11","conditions":"Hypercholesterolaemia","enrollment":520},{"nctId":"NCT00132717","phase":"PHASE3","title":"A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-01","conditions":"Hypercholesterolemia","enrollment":450},{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":"Hypercholesterolaemia","enrollment":153},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT00730132","phase":"","title":"Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-01","conditions":"Coronary Heart Disease, Hypercholesterolemia","enrollment":712},{"nctId":"NCT03510715","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-31","conditions":"Hypercholesterolemia","enrollment":18},{"nctId":"NCT01890967","phase":"PHASE2","title":"A Study of LY3015014 in Participants With High Cholesterol","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06","conditions":"Hypercholesterolemia","enrollment":527},{"nctId":"NCT04061824","phase":"PHASE4","title":"Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-05-24","conditions":"Hypertension, Dyslipidemias","enrollment":150},{"nctId":"NCT00127218","phase":"PHASE3","title":"High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2003-09","conditions":"Atherosclerosis, Cardiovascular Disease","enrollment":145},{"nctId":"NCT00385658","phase":"PHASE4","title":"Efficacy of Fluvastatin and Fenofibrate in Comparison to Simvastatin and Ezetimibe in Patients With Metabolic Syndrome","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-08","conditions":"Dyslipidemia","enrollment":75},{"nctId":"NCT00171288","phase":"PHASE3","title":"Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-08","conditions":"Dyslipidemia","enrollment":83},{"nctId":"NCT00814723","phase":"PHASE4","title":"Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2005-09","conditions":"Hypercholesterolemia","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":55,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"fluvastatin, ezetimibe","genericName":"fluvastatin, ezetimibe","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces LDL cholesterol through dual inhibition of cholesterol synthesis and intestinal absorption. Used for Hypercholesterolemia and mixed dyslipidemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}